The epidemiology of venous thromboembolism

Souto JC, Almasy L, Borrell M et al (2000) Genetic susceptibility to thrombosis and its relationship to physiological risk factors: the GAIT study. Genetic Analysis of Idiopathic Thrombophilia. Am J Hum Genet 67:1452–1459 Ariens RA, de Lange M, Snieder H, Boothby M, Spector TD, Grant PJ (2002) Activation markers of coagulation and fibrinolysis in twins: heritability of the prethrombotic state. Lancet 359:667–671 Larsen TB, Sorensen HT, Skytthe A, Johnsen SP, Vaupel JW, Christensen K (2003) Major genetic susceptibility for venous thromboembolism in men: a study of Danish twins. Epidemiology 14:328–332 Heit JA, Phelps MA, Ward SA, Slusser JP, Petterson TM, De Andrade M (2004) Familial segregation of venous thromboembolism. J Thromb Haemost 2:731–736 Zoller B, Ohlsson H, Sundquist J, Sundquist K (2013) Familial risk of venous thromboembolism in first-, second- and third-degree relatives: a nationwide family study in Sweden. Thromb Haemost 109:458–463 Zoller B, Li X, Sundquist J, Sundquist K (2012) A nationwide family study of pulmonary embolism: identification of high risk families with increased risk of hospitalized and fatal pulmonary embolism. Thromb Res 130:178–182 Zoller B, Li X, Sundquist J, Sundquist K (2012) Shared familial aggregation of susceptibility to different manifestations of venous thromboembolism: a nationwide family study in Sweden. Br J Haematol 157:146–148 Anderson FA Jr, Wheeler HB, Goldberg RJ et al (1991) A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med 151:933–938 Hansson PO, Welin L, Tibblin G, Eriksson H (1997) Deep vein thrombosis and pulmonary embolism in the general population. ‘The Study of Men Born in 1913′. Arch Intern Med 157:1665–1670 Silverstein MD, Heit JA, Mohr DN, Petterson TM, O’Fallon WM, Melton LJ 3rd (1998) Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 158:585–593 Oger E (2000) Incidence of venous thromboembolism: a community-based study in Western France. EPI-GETBP Study Group. Groupe d’Etude de la Thrombose de Bretagne Occidentale. Thromb Haemost 83:657–660 Cushman M, Tsai AW, White RH et al (2004) Deep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiology. Am J Med 117:19–25 Heit JA (2005) Venous thromboembolism: disease burden, outcomes and risk factors. J Thromb Haemost 3:1611–1617 Spencer FA, Emery C, Lessard D et al (2009) The Worcester Venous Thromboembolism study: a population-based study of the clinical epidemiology of venous thromboembolism. J Gen Intern Med 21:722–727 Naess IA, Christiansen SC, Romundstad P, Cannegieter SC, Rosendaal FR, Hammerstrom J (2007) Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost 5:692–699 Spencer FA, Emery C, Joffe SW et al (2009) Incidence rates, clinical profile, and outcomes of patients with venous thromboembolism. The Worcester VTE study. J Thromb Thrombolysis 28:401–409 Tagalakis V, Patenaude V, Kahn SR, Suissa S (2013) Incidence of and mortality from venous thromboembolism in a real-world population: the Q-VTE Study Cohort. Am J Med 126(832):e813–e821 Huang W, Goldberg RJ, Anderson FA, Kiefe CI, Spencer FA (2014) Secular trends in occurrence of acute venous thromboembolism: the Worcester VTE study (1985-2009). Am J Med 127(829–839):e825 Rothwell PM, Coull AJ, Giles MF et al (2004) Change in stroke incidence, mortality, case-fatality, severity, and risk factors in Oxfordshire, UK from 1981 to 2004 (Oxford Vascular Study). Lancet 363:1925–1933 Koton S, Schneider AL, Rosamond WD et al (2014) Stroke incidence and mortality trends in US communities, 1987 to 2011. JAMA 312:259–268 White RH, Zhou H, Romano PS (1998) Incidence of idiopathic deep venous thrombosis and secondary thromboembolism among ethnic groups in California. Ann Intern Med 128:737–740 Schneider D, Lilienfeld DE, Im W (2006) The epidemiology of pulmonary embolism: racial contrasts in incidence and in-hospital case fatality. J Natl Med Assoc 98:1967–1972 Zakai NA, McClure LA, Judd SE et al (2014) Racial and regional differences in venous thromboembolism in the United States in 3 cohorts. Circulation 129:1502–1509 Cheuk BL, Cheung GC, Cheng SW (2004) Epidemiology of venous thromboembolism in a Chinese population. Br J Surg 91:424–428 Klatsky AL, Armstrong MA, Poggi J (2000) Risk of pulmonary embolism and/or deep venous thrombosis in Asian-Americans. Am J Cardiol 85:1334–1337 White RH, Zhou H, Murin S, Harvey D (2005) Effect of ethnicity and gender on the incidence of venous thromboembolism in a diverse population in California in 1996. Thromb Haemost 93:298–305 Hooper WC, Holman RC, Heit JA, Cobb N (2002) Venous thromboembolism hospitalizations among American Indians and Alaska Natives. Thromb Res 108:273–278 Heit JA, O’Fallon WM, Petterson TM et al (2002) Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med 162:1245–1248 Spencer FA. Personal communication Heit JA, Sobell JL, Li H, Sommer SS (2005) The incidence of venous thromboembolism among Factor V Leiden carriers: a community-based cohort study. JTH 3:305–311 Prandoni P, Lensing AW, Cogo A et al (1996) The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 125:1–7 Heit JA, Mohr DN, Silverstein MD, Petterson TM, O’Fallon WM, Melton LJ 3rd (2000) Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med 160:761–768 Hansson PO, Sorbo J, Eriksson H (2000) Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors. Arch Intern Med 160:769–774 van Dongen CJ, Vink R, Hutten BA, Buller HR, Prins MH (2003) The incidence of recurrent venous thromboembolism after treatment with vitamin K antagonists in relation to time since first event: a meta-analysis. Arch Intern Med 163:1285–1293 Schulman S, Lindmarker P, Holmstrom M et al (2006) Post-thrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months. JTH 4:734–742 Prandoni P, Noventa F, Ghirarduzzi A et al (2007) The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. Haematologica 92:199–205 Spencer FA, Gore JM, Lessard D, Douketis JD, Emery C, Goldberg RJ (2008) Patient outcomes after deep vein thrombosis and pulmonary embolism: the Worcester Venous Thromboembolism Study. Arch Intern Med 168:425–430 Nieto JA, Camara T, Gonzalez-Higueras E et al (2008) Clinical outcome of patients with major bleeding after venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost 100:789–796 White RH, Chan WS, Zhou H, Ginsberg JS (2008) Recurrent venous thromboembolism after pregnancy-associated versus unprovoked thromboembolism. Thromb Haemost 100:246–252 Kyrle PA, Rosendaal FR, Eichinger S (2010) Risk assessment for recurrent venous thrombosis. Lancet 376:2032–2039 Verso M, Agnelli G, Ageno W et al (2012) Long-term death and recurrence in patients with acute venous thromboembolism: the MASTER registry. Thromb Res 130:369–373 Schulman S, Granqvist S, Holmstrom M et al (1997) The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group. N Engl J Med 336:393–398 Kearon C, Gent M, Hirsh J et al (1999) A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 340:901–907 Agnelli G, Prandoni P, Santamaria MG et al (2001) Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators. N Engl J Med 345:165–169 Schulman S, Rhedin AS, Lindmarker P et al (1995) A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group. N Engl J Med 332:1661–1665 Agnelli G, Prandoni P, Becattini C et al (2003) Extended oral anticoagulant therapy after a first episode of pulmonary embolism. Ann Intern Med 139:19–25 Prandoni P, Lensing AW, Prins MH et al (2002) Residual venous thrombosis as a predictive factor of recurrent venous thromboembolism. Ann Intern Med 137:955–960 Kyrle PA, Eichinger S (2003) The risk of recurrent venous thromboembolism: the Austrian Study on Recurrent Venous Thromboembolism. Wien Klin Wochenschr 115:471–474 Douketis JD, Foster GA, Crowther MA, Prins MH, Ginsberg JS (2000) Clinical risk factors and timing of recurrent venous thromboembolism during the initial 3 months of anticoagulant therapy. Arch Intern Med 160:3431–3436 Murin S, Romano PS, White RH (2002) Comparison of outcomes after hospitalization for deep venous thrombosis or pulmonary embolism. Thromb Haemost 88:407–414 Kyrle PA, Minar E, Bialonczyk C, Hirschl M, Weltermann A, Eichinger S (2004) The risk of recurrent venous thromboembolism in men and women. N Engl J Med 350:2558–2563 Laczkovics C, Grafenhofer H, Kaider A et al (2007) Risk of recurrence after a first venous thromboembolic event in young women. Haematologica 92:1201–1207 Kim TM, Kim JS, Han SW et al (2009) Clinical predictors of recurrent venous thromboembolism: a single institute experience in Korea. Thromb Res 123:436–443 Eichinger S, Hron G, Bialonczyk C et al (2008) Overweight, obesity, and the risk of recurrent venous thromboembolism. Arch Intern Med 168:1678–1683 Romualdi E, Squizzato A, Ageno W (2007) Abdominal obesity and the risk of recurrent deep vein thrombosis. Thromb Res 119:687–690 Garcia-Fuster MJ, Forner MJ, Fernandez C, Gil J, Vaya A, Maldonado L (2005) Long-term prospective study of recurrent venous thromboembolism in patients younger than 50 years. Pathophysiol Haemost Thromb 34:6–12 Heit JA, Cunningham JM, Petterson TM, Armasu SM, Rider DN, DEA M (2011) Genetic variation within the anticoagulant, procoagulant, fibrinolytic and innate immunity pathways as risk factors for venous thromboembolism. JTH 9:1133–1142 Agnelli G, Becattini C, Prandoni P (2004) Recurrent venous thromboembolism in men and women. N Engl J Med 351:2015–2018 Baglin T, Luddington R, Brown K, Baglin C (2003) Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet 362:523–526 Baglin T, Luddington R, Brown K, Baglin C (2004) High risk of recurrent venous thromboembolism in men. JTH 2:2152–2155 McRae S, Tran H, Schulman S, Ginsberg J, Kearon C (2006) Effect of patient’s sex on risk of recurrent venous thromboembolism: a meta-analysis. Lancet 368:371–378 Lijfering WM, Veeger NJ, Middeldorp S et al (2009) A lower risk of recurrent venous thrombosis in women compared with men is explained by sex-specific risk factors at time of first venous thrombosis in thrombophilic families. Blood 114:2031–2036 Le Gal G, Kovacs MJ, Carrier M et al (2010) Risk of recurrent venous thromboembolism after a first oestrogen-associated episode. Data from the REVERSE cohort study. Thromb Haemost 104:498–503 Christiansen SC, Lijfering WM, Helmerhorst FM, Rosendaal FR, Cannegieter SC (2010) Sex difference in risk of recurrent venous thrombosis and the risk profile for a second event. JTH 8:2159–2168 Douketis J, Tosetto A, Marcucci M et al (2011) Risk of recurrence after venous thromboembolism in men and women: patient level meta-analysis. BMJ 342:d813 Hutten BA, Prins MH, Gent M, Ginsberg J, Tijssen JG, Buller HR (2000) Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol 18:3078–3083 Pinede L, Ninet J, Duhaut P et al (2001) Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis. Circulation 103:2453–2460 Prandoni P, Lensing AW, Piccioli A et al (2002) Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 100:3484–3488 Louzada ML, Majeed H, Dao V, Wells PS (2011) Risk of recurrent venous thromboembolism according to malignancy characteristics in patients with cancer-associated thrombosis: a systematic review of observational and intervention studies. Blood Coagul Fibrinolysis 22:86–91 Louzada ML, Carrier M, Lazo-Langner A et al (2012) Development of a clinical prediction rule for risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism. Circulation 126:448–454 Chee CE, Ashrani AA, Marks RS et al (2014) Predictors of venous thromboembolism recurrence and bleeding among active cancer patients: a population-based cohort study. Blood 123:3972–3978 Iorio A, Kearon C, Filippucci E et al (2010) Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor: a systematic review. Arch Intern Med 170:1710–1716 Baglin T, Douketis J, Tosetto A et al (2010) Does the clinical presentation and extent of venous thrombosis predict likelihood and type of recurrence? A patient-level meta-analysis. JTH 8:2436–2442 Kovacs MJ, Kahn SR, Wells PS et al (2010) Patients with a first symptomatic unprovoked deep vein thrombosis are at higher risk of recurrent venous thromboembolism than patients with a first unprovoked pulmonary embolism. JTH 8:1926–1932 Schulman S, Svenungsson E, Granqvist S (1998) Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Duration of Anticoagulation Study Group. Am J Med 104:332–338 van den Belt AG, Sanson BJ, Simioni P et al (1997) Recurrence of venous thromboembolism in patients with familial thrombophilia. Arch Intern Med 157:2227–2232 Vossen CY, Conard J, Fontcuberta J et al (2005) Risk of a first venous thrombotic event in carriers of a familial thrombophilic defect. The European prospective cohort on thrombophilia (EPCOT). JTH 3:459–464 Brouwer JL, Lijfering WM, Ten Kate MK, Kluin-Nelemans HC, Veeger NJ, van der Meer J (2009) High long-term absolute risk of recurrent venous thromboembolism in patients with hereditary deficiencies of protein S, protein C or antithrombin. Thromb Haemost 101:93–99 den Heijer M, Willems HP, Blom HJ et al (2007) Homocysteine lowering by B vitamins and the secondary prevention of deep vein thrombosis and pulmonary embolism: a randomized, placebo-controlled, double-blind trial. Blood 109:139–144 Verhovsek M, Douketis JD, Yi Q et al (2008) Systematic review: D-dimer to predict recurrent disease after stopping anticoagulant therapy for unprovoked venous thromboembolism. Ann Intern Med 149(481–490):W494 Douketis J, Tosetto A, Marcucci M et al (2010) Patient-level meta-analysis: effect of measurement timing, threshold, and patient age on ability of D-dimer testing to assess recurrence risk after unprovoked venous thromboembolism. Ann Intern Med 153:523–531 Cosmi B, Legnani C, Tosetto A et al (2010) Usefulness of repeated D-dimer testing after stopping anticoagulation for a first episode of unprovoked venous thromboembolism: the PROLONG II prospective study. Blood 115:481–488 Palareti G, Cosmi B, Legnani C et al (2014) D-dimer to guide the duration of anticoagulation in patients with venous thromboembolism: a management study. Blood 124:196–203 Tan M, Mos IC, Klok FA, Huisman MV (2011) Residual venous thrombosis as predictive factor for recurrent venous thromboembolim in patients with proximal deep vein thrombosis: a sytematic review. Br J Haematol 153:168–178 Le Gal G, Carrier M, Kovacs MJ et al (2011) Residual vein obstruction as a predictor for recurrent thromboembolic events after a first unprovoked episode: data from the REVERSE cohort study. JTH 9:1126–1132 Zhu T, Martinez I, Emmerich J (2009) Venous thromboembolism: risk factors for recurrence. Arterioscler Thromb Vasc Biol 29:298–310 Cushman M, Glynn RJ, Goldhaber SZ et al (2006) Hormonal factors and risk of recurrent venous thrombosis: the prevention of recurrent venous thromboembolism trial. JTH 4:2199–2203 White RH, Murin S, Wun T, Danielsen B (2010) Recurrent venous thromboembolism after surgery-provoked versus unprovoked thromboembolism. JTH 8:987–997 Douketis JD, Crowther MA, Foster GA, Ginsberg JS (2001) Does the location of thrombosis determine the risk of disease recurrence in patients with proximal deep vein thrombosis? Am J Med 110:515–519 Eichinger S, Weltermann A, Minar E et al (2004) Symptomatic pulmonary embolism and the risk of recurrent venous thromboembolism. Arch of Internal Medicine 164:92–96 Jimenez D, Diaz G, Marin E, Vidal R, Sueiro A, Yusen RD (2006) The risk of recurrent venous thromboembolism in patients with unprovoked symptomatic deep vein thrombosis and asymptomatic pulmonary embolism. Thromb Haemost 95:562–566 Boutitie F, Pinede L, Schulman S et al (2011) Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants’ data from seven trials. BMJ 342:d3036 Rodger MA, Kahn SR, Wells PS et al (2008) Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy. CMAJ 179:417–426 Eichinger S, Heinze G, Jandeck LM, Kyrle PA (2010) Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna prediction model. Circulation 121:1630–1636 Tosetto A, Iorio A, Marcucci M et al (2012) Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH). JTH 10:1019–1025 Kyrle PA, Eichinger S (2012) Clinical scores to predict recurrence risk of venous thromboembolism. Thromb Haemost 108:1061–1064 Poli D, Palareti G (2013) Assessing recurrence risk following acute venous thromboembolism: use of algorithms. Curr Opin Pulm Med 19:407–412 den Exter PL, Kooiman J, Huisman MV (2013) Validation of the Ottawa prognostic score for the prediction of recurrent venous thromboembolism in patients with cancer-associated thrombosis. JTH 11:998–1000 Heit JA (2012) Estimating the incidence of symptomatic postoperative venous thromboembolism: the importance of perspective. JAMA 307:306–307 Yusuf H, Tsai J, Atrash HK, Boulet LP, Grosse SD (2012) Venous thromboembolism in adult hospitalizations - United States, 2007-2009. MMWR Morb Mortal Wkly Rep 61:401–404 Cohoon KP, Leibson CL, Ransom JE, et al (2015) Costs of venous thromboembolism associated with hospitalization for medical illness. Am J Manag Care 21(4):e255–e263 Cohoon KP, Leibson CL, Ransom JE, et al (2015) Direct medical costs attributable to venous thromboembolism among persons hospitalized for major operation: a population-based longitudinal study. Surgery 157:423–431 Cohoon KP, Leibson CL, Ransom JE, et al (2015) Direct medical costs attributalbe to cancer-associated venous thromboembolism: a population-based longitudinal study. J Oncol Pract Heit JA, Silverstein MD, Mohr DN, Petterson TM, O’Fallon WM, Melton LJ 3rd (1999) Predictors of survival after deep vein thrombosis and pulmonary embolism: a population-based, cohort study. Arch Intern Med 159:445–453 Goldhaber SZ, Visani L, De Rosa M (1999) Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet 353:1386–1389 Janata K, Holzer M, Domanovits H et al (2002) Mortality of patients with pulmonary embolism. Wien Klin Wochenschr 114:766–772 Andresen MS, Sandven I, Brunborg C et al (2011) Mortality and recurrence after treatment of VTE: long term follow-up of patients with good life-expectancy. Thromb Res 127:540–546 Agnelli G, Becattini C (2010) Acute pulmonary embolism. N Engl J Med 363:266–274 Konstantinides S, Geibel A, Olschewski M et al (1997) Association between thrombolytic treatment and the prognosis of hemodynamically stable patients with major pulmonary embolism: results of a multicenter registry. Circulation 96:882–888 Horlander KT, Mannino DM, Leeper KV (2003) Pulmonary embolism mortality in the United States, 1979-1998: an analysis using multiple-cause mortality data. Arch Intern Med 163:1711–1717 Tsai J, Grosse SD, Grant AM, Hooper WC, Atrash HK (2012) Trends in in-hospital deaths among hospitalizations with pulmonary embolism. Arch Intern Med 172:960–961 Heit JA, Silverstein MD, Mohr DN, Petterson TM, O’Fallon WM, Melton LJ 3rd (2000) Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 160:809–815 Cushman M, Folsom AR, Wang L et al (2003) Fibrin fragment D-dimer and the risk of future venous thrombosis. Blood 101:1243–1248 Smeeth L, Cook C, Thomas S, Hall AJ, Hubbard R, Vallance P (2006) Risk of deep vein thrombosis and pulmonary embolism after acute infection in a community setting. Lancet 367:1075–1079 Sweetland S, Green J, Liu B et al (2009) Duration and magnitude of the postoperative risk of venous thromboembolism in middle aged women: prospective cohort study. BMJ 339:b4583 Bezemer ID, van der Meer FJ, Eikenboom JC, Rosendaal FR, Doggen CJ (2009) The value of family history as a risk indicator for venous thrombosis. Arch Intern Med 169:610–615 Barsoum MK, Heit JA, Ashrani AA, Leibson CL, Petterson TM, Bailey KR (2010) Is progestin an independent risk factor for incident venous thromboembolism? A population-based case-control study. Thromb Res 126:373–378 Roach RE, Lijfering WM, Flinterman LE, Rosendaal FR, Cannegieter SC (2013) Increased risk of CVD after VT is determined by common etiologic factors. Blood 121:4948–4954 Heit JA, Melton LJ 3rd, Lohse CM et al (2001) Incidence of venous thromboembolism in hospitalized patients vs community residents. Mayo Clin Proc 76:1102–1110 Noboa S, Mottier D, Oger E (2006) Estimation of a potentially preventable fraction of venous thromboembolism: a community-based prospective study. JTH 4:2720–2722 Samama MM (2000) An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study. Arch Intern Med 160:3415–3420 Geerts WH, Bergqvist D, Pineo GF et al (2008) Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133:381S–453S Sweetland S, Parkin L, Balkwill A, Green J, Reeves G, Beral V (2013) Smoking, surgery, and venous thromboembolism risk in women: United Kingdom cohort study. Circulation 127:1276–1282 White RH, Zhou H, Romano PS (2003) Incidence of symptomatic venous thromboembolism after different elective or urgent surgical procedures. Thromb Haemost 90:446–455 Edmonds MJ, Crichton TJ, Runciman WB, Pradhan M (2004) Evidence-based risk factors for postoperative deep vein thrombosis. ANZ J Surg 74:1082–1097 Goldhaber SZ, Tapson VF (2004) A prospective registry of 5,451 patients with ultrasound-confirmed deep vein thrombosis. Am J Cardiol 93:259–262 Anderson FA Jr, Hirsh J, White K, Fitzgerald RH Jr (2003) Temporal trends in prevention of venous thromboembolism following primary total hip or knee arthroplasty 1996-2001: findings from the Hip and Knee Registry. Chest 124:349S–356S White RH, Gettner S, Newman JM, Trauner KB, Romano PS (2000) Predictors of rehospitalization for symptomatic venous thromboembolism after total hip arthroplasty. N Engl J Med 343:1758–1764 Parkin L, Sweetland S, Balkwill A, Green J, Reeves G, Beral V (2012) Body mass index, surgery, and risk of venous thromboembolism in middle-aged women: a cohort study. Circulation 125:1897–1904 Mantilla CB, Horlocker TT, Schroeder DR, Berry DJ, Brown DL (2003) Risk factors for clinically relevant pulmonary embolism and deep venous thrombosis in patients undergoing primary hip or knee arthroplasty. Anesthesiology 99:552–560 discussion 555A Zakai NA, Wright J, Cushman M (2004) Risk factors for venous thrombosis in medical inpatients: validation of a thrombosis risk score. JTH 2:2156–2161 Chopard P, Spirk D, Bounameaux H (2006) Identifying acutely ill medical patients requiring thromboprophylaxis. JTH 4:915–916 Barbar S, Noventa F, Rossetto V et al (2010) A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the padua prediction score. JTH 8:2450–2457 Rothberg MB, Lindenauer PK, Lahti M, Pekow PS, Selker HP (2011) Risk factor model to predict venous thromboembolism in hospitalized medical patients. J Hosp Med 6:202–209 Spyropoulos AC, Anderson FA Jr, Fitzgerald G et al (2011) Predictive and associative models to identify hospitalized medical patients at risk for VTE. Chest 140:706–714 Woller SC, Stevens SM, Jones JP et al (2011) Derivation and validation of a simple model to identify venous thromboembolism risk in medical patients. Am J Med 124(947–954):e942 Zakai NA, Callas PW, Repp AB, Cushman M (2013) Venous thrombosis risk assessment in medical inpatients: the medical inpatients and thrombosis (MITH) study. JTH 11:634–641 Samama MM, Combe S, Conard J, Horellou MH (2012) Risk assessment models for thromboprophylaxis of medical patients. Thromb Res 129:127–132 Rothberg MB (2014) Venous thromboembolism prophylaxis for medical patients: who needs it? JAMA Intern Med 174:1585–1586 Chew HK, Wun T, Harvey D, Zhou H, White RH (2006) Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 166:458–464 Blom JW, Vanderschoot JP, Oostindier MJ, Osanto S, van der Meer FJ, Rosendaal FR (2006) Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study. JTH 4:529–535 Kucuk O, Kwaan HC, Gunnar W, Vazquez RM (1985) Thromboembolic complications associated with L-asparaginase therapy. Etiologic role of low antithrombin III and plasminogen levels and therapeutic correction by fresh frozen plasma. Cancer 55:702–706 Liebman HA, Wada JK, Patch MJ, McGehee W (1982) Depression of functional and antigenic plasma antithrombin III (AT-III) due to therapy with L-asparaginase. Cancer 50:451–456 Zangari M, Anaissie E, Barlogie B et al (2001) Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood 98:1614–1615 Knight R, DeLap RJ, Zeldis JB (2006) Lenalidomide and venous thrombosis in multiple myeloma. N Engl J Med 354:2079–2080 Meier CR, Jick H (1998) Tamoxifen and risk of idiopathic venous thromboembolism. Br J Clin Pharmacol 45:608–612 Tafur AJ, Kalsi H, Wysokinski WE et al (2011) The association of active cancer with venous thromboembolism location: a population-based study. Mayo Clin Proc 86:25–30 Carrier M, Le Gal G, Wells PS, Fergusson D, Ramsay T, Rodger MA (2008) Systematic review: the Trousseau syndrome revisited: should we screen extensively for cancer in patients with venous thromboembolism? Ann Intern Med 149:323–333 Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW (2008) Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 111:4902–4907 Ay C, Dunkler D, Marosi C et al (2010) Prediction of venous thromboembolism in cancer patients. Blood 116:5377–5382 Merrer J, De Jonghe B, Golliot F et al (2001) Complications of femoral and subclavian venous catheterization in critically ill patients: a randomized controlled trial. JAMA 286:700–707 Decousus H, Quere I, Presles E et al (2010) Superficial venous thrombosis and venous thromboembolism: a large, prospective epidemiologic study. Ann Intern Med 152:218–224 Goldhaber SZ, Savage DD, Garrison RJ et al (1983) Risk factors for pulmonary embolism. The Framingham Study. Am J Med 74:1023–1028 Cogo A, Bernardi E, Prandoni P et al (1994) Acquired risk factors for deep-vein thrombosis in symptomatic outpatients. Arch Intern Med 154:164–168 Dalen JE (2003) Economy class syndrome: too much flying or too much sitting? Arch Intern Med 163:2674–2676 Kuipers S, Cannegieter SC, Middeldorp S, Robyn L, Buller HR, Rosendaal FR (2007) The absolute risk of venous thrombosis after air travel: a cohort study of 8,755 employees of international organisations. PLoS Med 4:e290 Chandra D, Parisini E, Mozaffarian D (2009) Meta-analysis: travel and risk for venous thromboembolism. Ann Intern Med 151:180–190 Watson HG, Baglin TP (2011) Guidelines on travel-related venous thrombosis. Br J Haematol 152:31–34 Ray JG, Mamdani M, Tsuyuki RT, Anderson DR, Yeo EL, Laupacis A (2001) Use of statins and the subsequent development of deep vein thrombosis. Arch Intern Med 161:1405–1410 Lacut K, Oger E, Le Gal G et al (2004) Statins but not fibrates are associated with a reduced risk of venous thromboembolism: a hospital-based case-control study. Fundam Clin Pharmacol 18:477–482 Glynn RJ, Danielson E, Fonseca FA et al (2009) A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med 360:1851–1861 Doggen CJ, Smith NL, Lemaitre RN, Heckbert SR, Rosendaal FR, Psaty BM (2004) Serum lipid levels and the risk of venous thrombosis. Arterioscler Thromb Vasc Biol 24:1970–1975 Prandoni P, Bilora F, Marchiori A et al (2003) An association between atherosclerosis and venous thrombosis. N Engl J Med 348:1435–1441 Marcucci R, Liotta AA, Cellai AP et al (2003) Increased plasma levels of lipoprotein(a) and the risk of idiopathic and recurrent venous thromboembolism. Am J Med 115:601–605 Tsai AW, Cushman M, Rosamond WD, Heckbert SR, Polak JF, Folsom AR (2002) Cardiovascular risk factors and venous thromboembolism incidence: the longitudinal investigation of thromboembolism etiology. Arch Intern Med 162:1182–1189 Sorensen HT, Horvath-Puho E, Pedersen L, Baron JA, Prandoni P (2007) Venous thromboembolism and subsequent hospitalisation due to acute arterial cardiovascular events: a 20-year cohort study. Lancet 370:1773–1779 Zoller B, Li X, Sundquist J, Sundquist K (2011) Venous thromboembolism does not share strong familial susceptibility with coronary heart disease: a nationwide family study in Sweden. Eur Heart J 32:2800–2805 Barsoum MK, Cohoon KP, Roger VL et al (2014) Are myocardial infarction and venous thromboembolism associated? Population-based case-control and cohort studies. Thromb Res 134:593–598 Folsom AR, Chamberlain A (2008) Lipoprotein(a) and venous thromboembolism. Am J Med 121:e17 Chamberlain AM, Folsom AR, Heckbert SR, Rosamond WD, Cushman M (2008) High-density lipoprotein cholesterol and venous thromboembolism in the Longitudinal Investigation of Thromboembolism Etiology (LITE). Blood 112:2675–2680 Chasan-Taber L, Stampfer MJ (1998) Epidemiology of oral contraceptives and cardiovascular disease. Ann Intern Med 128:467–477 Rosendaal FR (1999) Risk factors for venous thrombotic disease. Thromb Haemost 82:610–619 Gomes MP, Deitcher SR (2004) Risk of venous thromboembolic disease associated with hormonal contraceptives and hormone replacement therapy: a clinical review. Arch Intern Med 164:1965–1976 Grady D, Wenger NK, Herrington D et al (2000) Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study. Ann Intern Med 132:689–696 Grady D, Hulley SB, Furberg C (1997) Venous thromboembolic events associated with hormone replacement therapy. JAMA 278:477 Heit JA, Kobbervig CE, James AH, Petterson TM, Bailey KR, Melton LJ 3rd (2005) Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann Intern Med 143:697–706 Adomaityte J, Farooq M, Qayyum R (2008) Effect of raloxifene therapy on venous thromboembolism in postmenopausal women. A meta-analysis. Thromb Haemost 99:338–342 van Hylckama Vlieg A, Helmerhorst FM, Rosendaal FR (2010) The risk of deep venous thrombosis associated with injectable depot-medroxyprogesterone acetate contraceptives or a levonorgestrel intrauterine device. Arterioscler Thromb Vasc Biol 30:2297–2300 Smith NL, Heckbert SR, Lemaitre RN et al (2004) Esterified estrogens and conjugated equine estrogens and the risk of venous thrombosis. JAMA 292:1581–1587 Scarabin P-Y, Oger E, Plu-Bureau G (2003) Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 362(9382):428–432 James AH (2009) Venous thromboembolism in pregnancy. Arterioscler Thromb Vasc Biol 29:326–331 Danilenko-Dixon DR, Heit JA, Silverstein MD et al (2001) Risk factors for deep vein thrombosis and pulmonary embolism during pregnancy or post partum: a population-based, case-control study. Am J Obstet Gynecol 184:104–110 Roach RE, Lijfering WM, van Hylckama Vlieg A, Helmerhorst FM, Rosendaal FR, Cannegieter SC (2013) The risk of venous thrombosis in individuals with a history of superficial vein thrombosis and acquired venous thrombotic risk factors. Blood 122:4264–4269 Ludvigsson JF, Welander A, Lassila R, Ekbom A, Montgomery SM (2007) Risk of thromboembolism in 14,000 individuals with coeliac disease. Br J Haematol 139:121–127 Shantsila E, Lip GY, Chong BH (2009) Heparin-induced thrombocytopenia. A contemporary clinical approach to diagnosis and management. Chest 135:1651–1664 Tsai AW, Cushman M, Tsai MY et al (2003) Serum homocysteine, thermolabile variant of methylene tetrahydrofolate reductase (MTHFR), and venous thromboembolism: longitudinal Investigation of Thromboembolism Etiology (LITE). Am J Hematol 72:192–200 Den Heijer M, Lewington S, Clarke R (2005) Homocysteine, MTHFR and risk of venous thrombosis: a meta-analysis of published epidemiological studies. JTH 3:292–299 van Zaane B, Squizzato A, Huijgen R et al (2010) Increasing levels of free thyroxine as a risk factor for a first venous thrombosis: a case-control study. Blood 115:4344–4349 Severinsen MT, Engebjerg MC, Farkas DK et al (2011) Risk of venous thromboembolism in patients with primary chronic immune thrombocytopenia: a Danish population-based cohort study. Br J Haematol 152:360–362 Boyle S, White RH, Brunson A, Wun T (2013) Splenectomy and the incidence of venous thromboembolism and sepsis in patients with immune thrombocytopenia. Blood 121:4782–4790 Grainge MJ, West J, Card TR (2010) Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study. Lancet 375:657–663 Dentali F, Squizzato A, Brivio L et al (2009) JAK2V617F mutation for the early diagnosis of Ph- myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis. Blood 113:5617–5623 Barbui T, Carobbio A, Cervantes F et al (2010) Thrombosis in primary myelofibrosis: incidence and risk factors. Blood 115:778–782 Folsom AR, Lutsey PL, Astor BC, Wattanakit K, Heckbert SR, Cushman M (2010) Chronic kidney disease and venous thromboembolism: a prospective study. Nephrol Dial Transplant 25:3296–3301 Kayali F, Najjar R, Aswad F, Matta F, Stein PD (2008) Venous thromboembolism in patients hospitalized with nephrotic syndrome. Am J Med 121:226–230 Brodsky RA (2008) Paroxysmal nocturnal hemoglobinuria: stem cells and clonality. Hematology. Am Soc Hematol Educ Program pp 111–115 Bacani AK, Gabriel SE, Crowson CS, Heit JA, Matteson EL (2012) Noncardiac vascular disease in rheumatoid arthritis: increase in venous thromboembolic events? Arthritis Rheum 64:53–61 Holmqvist ME, Neovius M, Eriksson J et al (2012) Risk of venous thromboembolism in patients with rheumatoid arthritis and association with disease duration and hospitalization. JAMA 308:1350–1356 Arnulf I, Merino-Andreu M, Perrier A, Birolleau S, Similowski T, Derenne JP (2002) Obstructive sleep apnea and venous thromboembolism. JAMA 287:2655–2656 Peng YH, Liao WC, Chung WS et al (2014) Association between obstructive sleep apnea and deep vein thrombosis/pulmonary embolism: a population-based retrospective cohort study. Thromb Res 134:340–345 Austin H, Key NS, Benson JM et al (2007) Sickle cell trait and the risk of venous thromboembolism among blacks. Blood 110:908–912 Merkel PA, Lo GH, Holbrook JT et al (2005) Brief communication: high incidence of venous thrombotic events among patients with Wegener granulomatosis: the Wegener’s Clinical Occurrence of Thrombosis (WeCLOT) Study. Ann Intern Med 142:620–626